Current status of combined radiation therapy and androgen suppression in locally advanced prostate cancer: What is the way forward?

European Urology, Supplements

Volumn 9, Issue 11, 2010, Pages 788-793

  Bolla, Michel ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

Androgen deprivation therapy; Combined treatment; Prostate cancer; Radiotherapy

Indexed keywords

GONADORELIN DERIVATIVE;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; COMPUTER ASSISTED RADIOTHERAPY; DISEASE FREE SURVIVAL; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; REVIEW; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 78649813473     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.10.004     Document Type: Review

References (11)

1. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. http://www.uroweb.org/gls/pdf/Prostate%20Cancer%202010.pdf.
2. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-108.
3. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate. The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21:3972-3978.
4. Horwitz E.M., Bae K., Hanks G.E., et al. Ten-year follow-up of Radiation Therapy Oncology Group Protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26:2497-2504.
5. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma. Long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005, 61:1285-1290.
6. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997, 337:295-300.
7. Bolla M., Collette L., Van Tienhoven G., et al. Ten year update of long term adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study [abstract]. Int J Rad Oncol Biol Phys 2008, 72:S30.
8. Widmark A., Klepp O., Solberg A., et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373:301-308.
9. Bolla M., de Reijke T.M., Van Tienhoven G., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
10. Zelefsky M.J., Yamada Y., Kollmeier M.A., Shippy A.M., Nedelka M.A. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008, 53:1172-1179.
11. Zapatero A., Valcárcel F., Calvo F.A., et al. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study. Clin Oncol 2005, 23:6561-6568.